Investors

Investors
<picture><source type="image/webp" srcSet="/static/2cf241996b0d6d9b54351b76891640b8/18e05/Image-1.webp 740w,/static/2cf241996b0d6d9b54351b76891640b8/81bef/Image-1.webp 1480w,/static/2cf241996b0d6d9b54351b76891640b8/2d0b8/Image-1.webp 2960w" sizes="(min-width: 2960px) 2960px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 2960px) 2960px, 100vw" decoding="async" loading="lazy" src="/static/2cf241996b0d6d9b54351b76891640b8/c9eb6/Image-1.jpg" srcSet="/static/2cf241996b0d6d9b54351b76891640b8/bbd3f/Image-1.jpg 740w,/static/2cf241996b0d6d9b54351b76891640b8/087e6/Image-1.jpg 1480w,/static/2cf241996b0d6d9b54351b76891640b8/c9eb6/Image-1.jpg 2960w" alt="&lt;p&gt;Close up of a middle aged woman dressed in a blazer, sitting down while looking at another person in the foreground.&lt;/p&gt;
"/></picture>
Welcome to Mendus’ Investor Relations page. Mendus is listed on NASDAQ Stockholm under the ticker symbol IMMU. You will find all relevant information on the Mendus share in our Investors section.

Overview
Press releases
Events & presentations
Corporate Governance
Articles of Association
General meeting
Board of Directors
Corporate governance reports
Senior executives
Nomination committee
Remuneration and the remuneration committee
Auditors and audit committee
Scientific committee
Scientific advisory board
Archived transactions
Shareholder & stock info
Share monitor
Shareholders
Convertible bonds
Analyst coverage
Financial reports
Financial calendar
Letter from the CEOThe positive Phase 2 data we presented at the American Society for Hematology conference last December for our lead program vididencel (DCP-001) in acute myeloid leukemia (AML) provide the basis for broader positioning and, eventually, the path to market registration of vididencel as a new maintenance treatment in AML. We also reported the first positive clinical safety data with vididencel in ovarian cancer and completed the preparations for a next clinical trial with our intratumoral primer ilixadencel. We are very happy with the progress we have made on all fronts in 2022 and the continued commitment of our entire team to develop impactful new cancer therapies. For 2023, we have taken necessary steps to focus on our most value-generating projects.
To read the full letter from the CEO, please click here.
Latest Company PresentationView the latest company presentation
 
ASH 2022 WebcastWatch the replay
 
Mendus KOL Event – November 2022Watch the replay
 
Latest press releasesMarch 2023
Mendus to present positive interim data from the ALISON trial in ovarian cancer at the AACR Annual Meeting 2023
Durable Vaccine-Induced T-Cell Responses Observed in the Majority of Vididencel-Treated Patients...
Learn more
March 2023Regulatory Release
Mendus secures second shareholder loan from Van Herk Investments and reduces the number of outstanding convertible bonds with Negma Group
Mendus AB today announced that the Company has closed a second loan under the terms of the commitment from its largest shareholder Van Herk Investments...
Learn more
Upcoming EventsApril 2023
AACR Annual Meeting 2023
Mendus to present positive interim data from the ALISON trial in ovarian cancer at the AACR Annual Meeting. Members of Mendus' leadership team and Business Development team will participate.
Learn more
April 2023
Innovation for Health 2023
CEO Erik Manting will participate.
Learn more

Contact
Telephone+46 (0)8 732 8400
Emailinfo@mendus.com
<picture><source type="image/webp" srcSet="/static/411b7857055b0888002108e1bcc9e280/e64f1/heado.webp 100w,/static/411b7857055b0888002108e1bcc9e280/8b00d/heado.webp 200w,/static/411b7857055b0888002108e1bcc9e280/9c0a1/heado.webp 400w,/static/411b7857055b0888002108e1bcc9e280/88f3e/heado.webp 800w" sizes="(min-width: 400px) 400px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 400px) 400px, 100vw" decoding="async" loading="lazy" src="/static/411b7857055b0888002108e1bcc9e280/10998/heado.jpg" srcSet="/static/411b7857055b0888002108e1bcc9e280/93e3f/heado.jpg 100w,/static/411b7857055b0888002108e1bcc9e280/839ae/heado.jpg 200w,/static/411b7857055b0888002108e1bcc9e280/10998/heado.jpg 400w,/static/411b7857055b0888002108e1bcc9e280/a677a/heado.jpg 800w" alt="&lt;p&gt;Image of old buildings by a dock with boats laying in the water in the foreground.&lt;/p&gt;
"/></picture>
Head OfficeVästra Trädgårdsgatan 15

111 53 Stockholm

Sweden
<picture><source type="image/webp" srcSet="/static/99d97027eda87168e92d8d30678ace5b/e64f1/rdo.webp 100w,/static/99d97027eda87168e92d8d30678ace5b/8b00d/rdo.webp 200w,/static/99d97027eda87168e92d8d30678ace5b/9b01d/rdo.webp 400w,/static/99d97027eda87168e92d8d30678ace5b/08dc5/rdo.webp 800w" sizes="(min-width: 400px) 400px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 400px) 400px, 100vw" decoding="async" loading="lazy" src="/static/99d97027eda87168e92d8d30678ace5b/fa758/rdo.jpg" srcSet="/static/99d97027eda87168e92d8d30678ace5b/93e3f/rdo.jpg 100w,/static/99d97027eda87168e92d8d30678ace5b/839ae/rdo.jpg 200w,/static/99d97027eda87168e92d8d30678ace5b/fa758/rdo.jpg 400w,/static/99d97027eda87168e92d8d30678ace5b/3f065/rdo.jpg 800w" alt="&lt;p&gt;City image from a walkway, with a church and tall buildings in the background.&lt;/p&gt;
"/></picture>
R&D OfficesEmmy Noetherweg 2K 

2333 BK Leiden

The Netherlands
<picture><source type="image/webp" srcSet="/static/e29ab9df2993f219c72ad7f14f67fc4a/e64f1/go.webp 100w,/static/e29ab9df2993f219c72ad7f14f67fc4a/8b00d/go.webp 200w,/static/e29ab9df2993f219c72ad7f14f67fc4a/9c0a1/go.webp 400w,/static/e29ab9df2993f219c72ad7f14f67fc4a/88f3e/go.webp 800w" sizes="(min-width: 400px) 400px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 400px) 400px, 100vw" decoding="async" loading="lazy" src="/static/e29ab9df2993f219c72ad7f14f67fc4a/10998/go.jpg" srcSet="/static/e29ab9df2993f219c72ad7f14f67fc4a/93e3f/go.jpg 100w,/static/e29ab9df2993f219c72ad7f14f67fc4a/839ae/go.jpg 200w,/static/e29ab9df2993f219c72ad7f14f67fc4a/10998/go.jpg 400w,/static/e29ab9df2993f219c72ad7f14f67fc4a/a677a/go.jpg 800w" alt="&lt;p&gt;Overview image of a city, shot in low sunlight from a far distance.&lt;/p&gt;
"/></picture>
Gothenburg OfficeMendus C/O AstraZeneca BioventureHub

Pepparedsleden 1

431 83 Mölndal

Sweden

.FullWidthImage-module--bg-image-mobile--ba5fc.FullWidthImage-module--hide-in-mobile--9cd89.gbi--1479869476-6JzsPoV2LfRxFq2gEpsCkz:before { opacity: 1; background-image: url('/static/a32348a89302674e113dc101e935b7b3/afb86/about-us-mobile.png'); }

News & eventsAt Mendus, we share a strong commitment to improve the lives of people with cancer.
News & Events

Letter from the CEO

Latest Company Presentation

ASH 2022 Webcast

Mendus KOL Event – November 2022

Latest press releases

Mendus to present positive interim data from the ALISON trial in ovarian cancer at the AACR Annual Meeting 2023

Mendus secures second shareholder loan from Van Herk Investments and reduces the number of outstanding convertible bonds with Negma Group

Upcoming Events

AACR Annual Meeting 2023

Innovation for Health 2023

Contact

Telephone

Email

Head Office

R&D Offices

Gothenburg Office

News & events

Keep up to date